Abstract
Prostate cancer is the most incident neoplasm in men in the world. This neoplasm affects approximately 32% of the male population. Among the chemotherapeutics recently employed in therapy, we highlight the abiraterone, which acts in inhibition of the enzyme CYP17 (responsible for the synthesis of androgens). Abiraterone was approved by the Food and Drug Administration (FDA) in 2012 for us…